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Integrative Physiology and Experimental Medicine
Systemic and Targeted Delivery of Semaphorin 3A Inhibits
Tumor Angiogenesis and Progression in Mouse
Tumor Models
Andrea Casazza, Xi Fu, Irja Johansson, Lorena Capparuccia, Fredrik Andersson, Alice Giustacchini,
Mario Leonardo Squadrito, Mary Anna Venneri, Massimiliano Mazzone, Erik Larsson, Peter Carmeliet,
Michele De Palma, Luigi Naldini, Luca Tamagnone, Charlotte Rolny
Objective—The role of semaphorins in tumor progression is still poorly understood. In this study, we aimed at elucidating
the regulatory role of semaphorin 3A (SEMA3A) in primary tumor growth and metastatic dissemination.
Methods and Results—We used 3 different experimental approaches in mouse tumor models: (1) overexpression of
SEMA3A in tumor cells, (2) systemic expression of SEMA3A following liver gene transfer in mice, and (3)
tumor-targeted release of SEMA3A using gene modified Tie2-expressing monocytes as delivery vehicles. In each of
these experimental settings, SEMA3A efficiently inhibited tumor growth by inhibiting vessel function and increasing
tumor hypoxia and necrosis, without promoting metastasis. We further show that the expression of the receptor
neuropilin-1 in tumor cells is required for SEMA3A-dependent inhibition of tumor cell migration in vitro and metastatic
spreading in vivo.
Conclusion—In sum, both systemic and tumor-targeted delivery of SEMA3A inhibits tumor angiogenesis and tumor
growth in multiple mouse models; moreover, SEMA3A inhibits the metastatic spreading from primary tumors. These
data support the rationale for further investigation of SEMA3A as an anticancer molecule. (Arterioscler Thromb Vasc
Biol. 2011;31:741-749.)
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Semaphorins are a highly conserved family of moleculesoriginally identified as axon guidance factors.1,2 Notably,
over the past few years, distinct semaphorins have been
implicated in additional biological processes, including an-
giogenesis, immune regulation, and cancer.3,4
See accompanying article on page 721
Semaphorin function is mediated by a family of plasma
membrane receptors, the plexins.5 However, most secreted
semaphorins (including semaphorin 3A [SEMA3A]) cannot
bind to plexins directly; rather, they interact with plexin-
associated coreceptors, namely neuropilin-1 (NP1) and
neuropilin-2 (NP2).3,5 Interestingly, NPs also bind vascular
endothelial growth factor family members and associate in
complex with vascular endothelial growth factor receptors,6
playing a crucial role in angiogenesis beyond axon guidance.3
In particular, SEMA3A signaling is fully dependent on the
receptor NP1, whereas little is known about the requirement
of specific plexins in its receptor complex.
So far, SEMA3A has been reported to inhibit the growth of
certain experimental tumors7 and to regulate endothelial cell
migration and apoptosis in vitro,8,9 as well as arteriogenesis in
the muscle,10 skin vessel permeability,11 and tumor angiogen-
esis in vivo.12 However, the functional significance of
SEMA3A signaling as a molecular target to control tumor
progression is still poorly understood. Generally, tumor blood
vessels display a chaotic architecture that leads to impaired
tumor perfusion, elevated tissue hypoxia, and substantial cell
death. It has been shown that antiangiogenic treatments
targeting vascular endothelial growth factor signaling can
disrupt tumor blood vessels and increase tumor necrosis.
However, these therapies, although they cause transient
tumor shrinkage, also elicit a prometastatic program in the
tumor cells that is driven by hypoxia.13,14 Therefore, strate-
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gies that concomitantly target endothelial cells and prevent
tumor cell spreading are needed. Here, we show that sys-
temic, as well as tumor-targeted, delivery of SEMA3A
inhibits tumor growth in multiple mouse models. This is
achieved through SEMA3A-mediated inhibition of blood
vessel function, whereas metastatic dissemination is hindered
via NP1-mediated signaling in tumor cells.
Methods
Tumor Cell Lines
Tumor cell lines were grown in standard medium supplemented with
L-glutamine and 10% fetal bovine serum (Sigma). 4T1 and 66cl4
spontaneous mouse mammary carcinoma cells were originally de-
rived from a single spontaneous tumor arisen in a BALB/cfC3H
mouse, isolated by 60 M 6-thioguanine in vitro selection, and
kindly provided by Dr F. Miller (Michigan Cancer Foundation,
Detroit, MI).15 MDA-MB-435 cells are undifferentiated tumor cells
derived from either human mammary carcinoma or, as recently
found, from human melanoma.16
Lentiviral Vectors
The LV constructs expressing green fluorescent protein (GFP) under
different promoters: i.e. Tie2, phosphoglycerate kinase (PGK) and
cytomegalovirus (CMV) were previously described.17 The Tie2-3A,
PGK-3A, and CMV-3A LVs were generated by cloning the mouse
Sema3A cDNA in place of GFP into the Tie2-GFP or PGK-GFP LV
or human SEMA3A cDNA into the CVM-GFP LV, respectively.
Concentrated vesicular stomatitis virus-G protein (VSV-G)-
pseudotyped LV stocks were produced and titrated as described
previously.18 Tumor cells were transduced by incubation with
concentrated LVs for 8 to 12 hours in the presence of 8 g/mL
polybrene.
SDS-PAGE and Western Immunoblotting
Cellular proteins were solubilized in 1% Triton X-100–containing
extraction buffer plus inhibitors, as previously described.18 Equal
amount of proteins were separated by SDS-PAGE, transferred to
nitrocellulose membranes and probed with antibodies directed
against myc-tag (9E10, Santa Cruz Biotechnology), NP1 (R&D
Systems), or -actin (Santa Cruz Biotechnology), followed by
detection using the appropriate secondary antibody and ECL system
(Amersham).
Gene Knockdown
NP1 expression was stably knocked down in 4T1 cancer cells using
a LV containing a gene-targeted short hairpin RNA against NP1 and
a puromycin resistance cassette (Sigma Mission, NM_009152).
Cell Growth Assay
Tumor cells were plated in multiple 96-well dishes (Costar) at an
initial density of 1103 cells/well. After 24 hours of serum starva-
tion, the cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with L-glutamine and 1% fetal bovine serum for 1, 2,
3, and 4 days. Cells were fixed with 11% glutaraldehyde and then
stained with 0.5% crystal violet in 20% methanol. The dye was
eluted with 10% v/v glacial acetic acid, and the absorbance at 595
nm was determined by using a Titertek Multiskan reader.
Cell Migration Assay
Cell motility was assayed using Transwell chamber inserts (Costar,
Cambridge, MA) with a porous polycarbonate membrane (8 mol/L
pore size), as described previously.19 Briefly, the lower side of the
filter was coated with 10 g/mL fibronectin. Approximately 1105
cells were added in the upper chamber and allowed to migrate
through the filter toward the lower chamber containing serum free
medium (0.2% bovine serum albumin) with or without SEMA3A, in
the presence of 15 g/mL purified anti-NP1 blocking antibody20 or
an unrelated antibody (anti-VSV-G). Cell migration was allowed for
16 to 18 hours; the cells adherent to the upper side of the filter were
mechanically removed, whereas those migrated to the lower side
were fixed with 11% glutaraldehyde and stained with crystal violet.
The dye was solubilized in 10% acetic acid to measure absorbance at
595 nm in a microplate reader.
Mouse Tumor Models
Six- to 8-week-old CD1 athymic mice and Balb/c mice were
purchased from Charles River Laboratory (Calco, Milan, Italy).
FVB/Tie2-GFP transgenic mice were generated by LV-mediated
transgenesis, as described.17 For tumorigenesis experiments, depend-
ing on the cancer cell line used, 2106 MDA-MB-435, 1106
66cl4, or 1106 4T1 cells were injected subcutaneously into the
flank or the mammary fat pad of anesthetized animals. Tumor size
was measured externally using a caliper, and tumor volume was
estimated using the following equation: V4/3(d/2)2D/2,
where d is the minor tumor axis and D is the major tumor axis. Mice
were typically euthanized 3 weeks after tumor cell injection (unless
otherwise indicated in the manuscript), and tumors weighted after
dissection. Superficial pulmonary metastases were contrasted by
black India-ink airways infusion, and counted on dissected lung
lobes under a stereoscopic microscope. For orthotopic tumor cell
injection, 1106 4T1 or 1106 4T1 66cl4 cells were resuspended in
40 L of phosphate-buffered saline and injected into the second
mammary fat pad of anesthetized Balb/c mice. Mice were euthanized
after 15 or 19 days, respectively, and tumor and lungs were analyzed
as described above. For systemic delivery of SEMA3A in vivo,
concentrated PGK-3A and control LVs were administered by tail
vein injection in 6- to 8-week-old Balb/c mice, 2 weeks before
subcutaneous tumor cell injection.
All animal procedures were performed according to protocols
approved by the animal experimentation supervising boards of the
University of Torino, Fondazione San Raffaele del Monte Tabor
(Milan, Italy), and Uppsala University.
Experimental Metastasis Assays
4T1 cancer cells (2.5105 cells) were injected in the lateral tail vein
of CD1 athymic mice; the formation of metastatic colonies in the
lungs was analyzed 8 days later by black India ink airways infusion,
as described above. For short-term experiments evaluating the
metastatic extravasation of fluorescent 4T1 cells, we labeled cancer
cells in culture by a short incubation with 10 mol/L CFDA SE
Vybrant cell tracker (Molecular probes) according to the manufac-
turer’s instructions, before cell injection in the tail vein.21 Tumor cell
colonization of lung tissue was analyzed 48 hours later in at least 5
pairs of lungs in each experimental group (10 independent micro-
scopic fields/lung) using the Metamorph software.
Metastatic Cell Clonogenic Assays
These assays were performed as described previously.15 After
euthanasia, the lungs, lymph nodes, brain and liver were removed
from tumor-bearing mice, minced into pieces, and incubated with a
cocktail containing 1.5 mg/mL collagenase type IV (Sigma) and 2
mg/mL dispase (Sigma) at 37°C. Tissue samples were then mechan-
ically dispersed and passed through 19- and 25-gauge needles to
form a single cell suspension, which was plated out in complete
culture medium supplemented with 60 mol/L 6-thioguanine. After
10 to 12 days, growing colonies were fixed with methanol, stained
with crystal violet, and counted under a dissection microscope.
Hematopoietic Stem/Progenitor Cell Transduction
and Transplantation
Six-week-old female CD1 athymic, FVB, and FVB/Tie2-GFP and
mice were killed with CO2, and their bone marrow (BM) was
harvested by flushing the femurs and the tibias. Lineage-negative
cells enriched in hematopoietic stem/progenitor cells were isolated
from BM cells using a cell purification kit (Stem Cell Technologies)
and transduced by concentrated LVs, as described.22,23 Briefly, 106
cells/mL were transduced with a LV dose equivalent to 3 to 4 g/mL
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HIV p24 (for Tie2-Sema3A and PGK-Sema3A LVs) or 108 GFP
transducing units/mL (for Tie2-GFP and PGK-GFP LVs) for 12
hours in serum-free StemSpan medium (Stem Cell Technologies)
containing a cocktail of cytokines (interleukin-3 [10 ng/mL],
interleukin-6 [20 ng/mL], SCF [100 ng/mL], and Fms-related ty-
rosine kinase 3 ligand [10 ng/mL], all from Serotec). After trans-
duction, 106 cells were infused into the tail vein of lethally irradiated,
6-week-old female CD1 athymic mice (radiation doses: 975 cGy).
Vector copy number in BM cells was measured by quantitative
polymerase chain reaction of vector sequences at the end of the
experiments, as described.24 Colony forming cell assays were per-
formed as described.22,23 The engraftment of hematopoietic stem/
progenitor cells transduced with the Tie2-SEMA3A-myc LV was
assessed in transplanted mice by anti-Tie2 and anti-myc immuno-
staining of circulating cells, using a BD FACSCanto (BD Biosci-
ence) analyzer.
Hypoxia and Tumor Perfusion
Tumor hypoxia was detected 2 hours after injection of 60 mg/kg
pimonidazole hydrochloride in tumor-bearing mice. Mice were then
euthanized, and tumors were harvested. To detect the formation of
pimonidazole adducts, tumor paraffin sections were immunostained
with Hypoxyprobe-1-Mab1 (Hypoxyprobe kit, Chemicon) following
the manufacturer’s instructions. Blood vessel permeability was
detected by intravenous injection of 0.05 mg of 70-kDa fluorescein
isothiocyanate (FITC)–conjugated dextran or biotin-conjugated dex-
tran (Molecular Probes) and of 0.05 mg of FITC-conjugated Tamato
Lectin (Vector Laboratories) in tumor-bearing mice; this relatively
small molecule extravasates readily from leaky tumor blood ves-
sels.25,26 Ten minutes later, mice were perfused by intracardiac
injection of saline and 2% paraformaldehyde (5 minutes) and the
tumors harvested and frozen in OCT compound. Blood vessel
permeability was analyzed by measuring the area of extravasated
dextran. Blood vessel perfusion was analyzed by injecting 0.05 mg
of nonpermeable high-molecular-weight tetramethylrhodamine-
labeled dextran (2 MDa, Molecular Probes) in tumor-bearing mice,
10 minutes before tumor excision.25 Tumors were then fixed in 4%
paraformaldehyde for 2 hours and frozen in OCT compound for
immunofluorescence analysis.
Histological Analysis
Tumors samples were frozen in OCT compound, cut in 10-m thick
sections, and immunostained with the appropriate antibodies, di-
rected to cleaved caspase-3 (5A1E, Cell Signaling), myc (9E10,
Santa Cruz Biotechnology), CD31, CD11b (BD Biosciences), F4/80
(Serotec), NG2 (Millipore), LYVE-1 (R&D Systems), Tie2 (eBio-
secences), -smooth muscle actin (-SMA)–FITC (Sigma), and
cleaved caspase-3 (Cell Signaling). Streptavidin and all secondary
antibodies were conjugated with Alexa Fluor 488 or Alexa Fluor 546
fluorochromes (Molecular Probes). Cell nuclei were labeled with
4,6-diamidino-2-phenylindole (Invitrogen Corp). Multiple indepen-
dent fields from sections of at least 4 tumors for each experimental
condition were analyzed by using a Leica DM IRBM microscope, a
Nikon TE300 Eclipse inverted fluorescence microscope, or a LSM
510 META confocal microscope and quantified by ImageJ software.
Statistical Analyses
Throughout the study, graphs always show average valuesstandard
deviation (SD) unless otherwise indicated. Statistical analyses were
performed by unpaired Student t test or 2-way ANOVA, as indicated.
Stars in the graphs indicate significance, as detailed in the figure
legends. Differences were considered statistically significant at
P0.05.
Results
SEMA3A Inhibits Tumor Growth and
Metastatic Progression
To investigate the role of SEMA3A in tumor cell behavior
and progression, we transduced 3 different tumor cell lines
(4T1 and 66cl4 mammary carcinoma and MDA-MB-435
melanoma cells) with a SEMA3A-expressing LV, and ob-
tained 3A cells. Control cells were generated by transducing
the aforementioned tumor cell lines with a LV lacking the
SEMA3A cDNA (referred to as empty vector [EV] cells). We
confirmed SEMA3A expression in transduced cells by West-
ern blotting (Figure 1A and Supplemental Figure IA, avail-
able online at http://atvb.ahajournals.org). Notably, in addi-
tion to endothelial cells, the SEMA3A receptor NP1 is
expressed in most tumor cells, including those used in our
study (see Supplemental Figure II). Although it has been
reported that SEMA3A can inhibit the growth of certain
tumor cell lines in an NP1-dependent manner,7 in our
experiments, SEMA3A overexpression did not affect tumor
cell proliferation, even on serum deprivation (Figure 1B and
1C and Supplemental Figure IB). However, SEMA3A
strongly inhibited tumor cell migration via NP1, as demon-
strated by using an NP1-blocking antibody (Figure 1D and 1E
and Supplemental Figure IC).
Despite the fact that SEMA3A autocrine loop in tumor
cells did not affect cell proliferation or survival in vitro, when
these engineered cells were implanted in vivo, we found that
tumor growth was strongly inhibited by SEMA3A expression
(Figure 1F and 1G and Supplemental Figure ID and IH).
Moreover, 3A tumor-bearing mice displayed fewer sponta-
neous lung metastatic nodules compared with controls (Fig-
ure 1H and Supplemental Figure IE). Because SEMA3A
proved to actively inhibit tumor cell migration in vitro, we
aimed at better understanding the role of SEMA3A in
controlling metastatic dissemination. We then introduced
fluorescently labeled 4T1-EV and 4T1–3A tumor cells in
the tail vein, and 48 hours postinjection, we scored the
number of tumor cells colonizing the lungs. Notably,
SEMA3A expression strongly reduced the number of tumor
cells that successfully extravasated and colonized the lungs
(Figure 1I), indicating that this semaphorin can directly
regulate metastasis formation.
4T1 tumor cells are known to spread to additional
metastatic sites beyond the lungs, such as lymph nodes,
liver and brain, whereas 66cl4 mainly spread via the
lymphatic route to the lungs.15 To investigate whether
SEMA3A also affects metastatic dissemination to other
distant organs, we injected 4T1 and 66cl4 control-EV or
3A cells in the mammary fat pad of wild-type female
mice to produce orthotopic mammary tumors. After 15
days, we euthanized the mice and harvested the liver,
brain, lungs, draining lymph nodes and blood. Dissociated
cells from the different organs were then subjected to
clonogenic assays in culture, in the presence of the
selection drug 6-thioguanine, for which both 4T1 and
66cl4 cells carry the resistance gene.15,27 In line with
previous reports,15 66cl4-EV tumor cells formed several
colonies from lymph nodes and few colonies from the lung
(Figure 1J), but none from liver, brain, or blood. On the
other hand, 4T1-EV tumor cells readily formed tumor cell
colonies from the lung and, to a lesser extent, from liver,
lymph nodes, and brain (Figure 1K). SEMA3A expression
in 66cl4 and 4T1 tumor cells significantly decreased the
number of colony-forming metastatic cells in each of the
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analyzed organs (Figure 1J and 1K). Interestingly, al-
though the number of colonies derived from blood was
low, it was also reduced in 4T1–3A tumor-bearing mice
(data not shown).
SEMA3A Inhibits Tumor Growth and Metastasis
Via Independent Signaling in Stromal and
Cancer Cells
Because SEMA3A has been shown previously to regulate
angiogenesis, we aimed at dissecting the functional relevance
of SEMA3A signaling in cancer cells and in the tumor
microenvironment. To this end, we knocked down the ex-
pression of the obligate SEMA3A-receptor NP1 in 4T1-EV
and 4T1–3A tumor cells by RNA interference-mediated
technology and injected the resultant cells subcutaneously in
mice (Figure 2A). Notably, NP1 gene knockdown did not
alter the growth of 4T1-EV or 4T1–3A cells in culture (not
shown), nor that of the tumors formed in vivo (Figure 2B),
suggesting that SEMA3A-induced inhibition of tumor growth
is independent from NP1 expression by tumor cells. More-
over, although NP1 gene knockdown did not affect the
metastatic dissemination of control 4T1-EV cells, it led to a
significant increase of lung metastasis formed by 4T1–3A
cells (Figure 2C). These data suggest that SEMA3A-mediated
suppression of metastatic dissemination depends on NP1-
mediated signaling in cancer cells.
SEMA3A Inhibits Tumor Growth Via Paracrine
Effects on Tumor Vasculature
The findings above strongly suggested that SEMA3A-
dependent inhibition of tumor growth seen in our experiments
was due to a paracrine effect in the tumor microenvironment.
To study the implicated mechanisms, we therefore analyzed
tissue sections derived from primary tumors. We found that
4T1- and 66cl4–3A tumors displayed 25% increased ne-
crotic areas compared with controls (Supplemental Figure
III). Moreover, SEMA3A tumors displayed higher propor-
tions of the apoptotic marker cleaved caspase-3 in tumor and
endothelial cells compared with controls (Figure 3A, Supple-
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was quantified by staining with crystal violet (see Methods for
details). D and E: Cancer cell migration was analyzed by using
Transwell inserts (see Methods). EV-control and SEMA3A tumor
cells were allowed to spontaneously migrate through a semiperme-
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mental Figure IF, and data not shown). Consistently,
SEMA3A expression by tumor cells was associated with
reduced vascular area and vessel density (Figure 3B, Supple-
mental Figure IG, and data not shown). To further investigate
whether SEMA3A had a direct effect on the tumor endothe-
lium, SEMA3A-expressing MDA-MB-435 tumor cells were
cocultured with primary human endothelial cells in vitro.
Staining for CD31 and cleaved caspase-3 revealed that
SEMA3A induced endothelial cell apoptosis (Supplemental
Figure IV). These data indicate direct proapoptotic effects of
SEMA3A on endothelial cells.
Endothelial cell survival often correlates with the extent
of pericyte coverage of endothelial cells in blood vessels.28
Double staining for CD31 and the pericyte markers
-SMA and NG2 indicated that SEMA3A expression by
tumor cells impaired pericyte coverage of tumor blood
vessels (Figure 3C).
Because Sema3A reduced 66cl4 tumor cell spreading to
lungs and lymphatics, we investigated whether SEMA3A-
expressing tumors displayed any defects in lymphangiogen-
esis. To this end, we stained tumor sections with antibodies
against LYVE-1, which labels lymphatic vessels and a subset
of F4/80 tumor-associated macrophages.29 Interestingly,
3A tumors displayed fewer lymphatic vessels, as shown by
the reduced relative area of LYVE-1F4/80–CD31– vascular
structures (Supplemental Figure V).
Systemic Delivery of SEMA3A Efficiently Inhibits
Tumor Progression
Once a tumor has disseminated to distant organs, the local
delivery of tumor suppressor molecules may not be a thera-
peutically feasible strategy. Thus, we assessed the potential
antitumor activity of SEMA3A in a model of systemic
delivery in vivo. We used a previously validated strategy to
achieve systemic expression of secreted factors in tumor-
recipient mice.30 On injection in the venous circulation, LVs
preferentially transduce the liver and the spleen, where they
establish a stable source of the transgene product.31 By this
approach, we generated mice stably expressing SEMA3A
(here referred to as s-SEMA3A mice), or control mice (s-EV
mice). SEMA3A expression was detected in the liver by
immunohistochemistry (Supplemental Figure VI) and in
blood samples by ELISA (estimated levels: 95% confidence
interval77.06 to 94.58 ng/mL). SEMA3A-treated mice did
not display histological abnormalities or increased apoptosis
in the liver (data not shown), nor did they show any
significant change in blood lymphocyte or erythrocyte counts
and hemoglobin levels (data not shown).
4T1 or 66cl4 metastatic mammary carcinoma cells were
then transplanted subcutaneously in syngeneic s-Sema3A and
control mice. Analogously to what was observed on
SEMA3A overexpression in cancer cells, the systemic ex-
pression of SEMA3A efficiently inhibited 4T1 and 66cl4
tumor growth (Figure 4A) and metastatic dissemination
in mice (Figure 4B). Notably (and consistent with data shown
in Figure 1D and 1E), 4T1 and 66cl4 tumor cell migration in
vitro was strongly inhibited by exogenous SEMA3A (Figure
4C). To further elucidate the antimetastatic effect of
SEMA3A, systemic delivery of SEMA3A was compared
with its overexpression in 4T1–3A cells, in a model of
experimental lung metastasis that is independent of the
growth of primary tumors. Both systemic and tumor cell-
based expression of SEMA3A impaired the formation of lung
metastatic colonies by 4T1 cells systemically injected in the
mouse circulation (Figure 4D), further supporting the hypoth-
esis that SEMA3A has a direct effect on tumor cell extrava-
sation and lung colonization.
We then investigated whether the systemic delivery of
SEMA3A produced the same effects on tumor vasculature
and apoptosis in primary tumors as its overexpression in
tumor cells. CD31 staining of tumor sections revealed that the
relative vessel area was reduced in 4T1 and 66cl4 tumors
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Figure 3. SEMA3A inhibits tumor angiogenesis. A, 66cl4-EV
and -3A and 4T1-EV and -3A tumor sections were subjected
to immunostaining for activated-caspase3 to detect apoptotic
cells (in green), CD31 marker was stained to identify endothelial
cells (red), and TOPRO3 stained all nuclei (blue). SEMA3A
expression increased the fraction of vessels containing apoptot-
ic cells and the apoptotic index of cancer cells (ie, caspase
cells/total cell number) (n6; *P0.05, ***P0.001). White
arrows point to apoptotic vessels, and green arrows point to
apoptotic tumor cells. The images depict representative 4T1-EV
and -3A tumor sections. Scale bars, 20 m. B, Tumor vascula-
ture was analyzed in tissue sections as described above by
CD31 staining. Both vessel density and relative (%) vessel area
were reduced in 66cl4 and 4T1 tumors expressing SEMA3A
compared with controls (n6; **P0.01, *P0.05). The images
depict representative 66cl4-EV and 66cl4-3A tumors sections.
Scale bars, 50 m. C, Tissue sections as described above were
costained for endothelial marker CD31 and the pericyte markers
-SMA (upper row) or NG2 (lower row) to assess number of
vessels coated with pericytes. Tumor vasculature was remark-
ably depleted of mural cells in 66cl4–3A and 4T1–3A com-
pared with controls (n6, **P0.01, *P0.05). The images
depict representative 4T1-EV and -3A tumor sections. Scale
bars, 20 m.
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grown in s-SEMA3A mice compared with those in control
s-EV mice (Figure 4E). Consistently, the systemic delivery of
SEMA3A enhanced tumor cell and blood vessel apoptosis
(visualized by staining for cleaved caspase-3; Figure 4F) and
reduced the number of tumor blood vessels covered with
NG2- or -SMA-expressing pericytes (Figure 5A). A reduced
pericyte coverage often correlates with increased vessel
permeability and poor vessel functionality,32,33 which may
lead to increased tumor hypoxia, conditions that were previ-
ously found to favor tumor cell intravasation and to fuel the
metastatic spreading.13,14,34 We then measured tumor blood
vessel permeability by systemic injection of the readily
diffusible 70-kDa FITC-conjugated dextran in tumor-
bearing mice. Notably, tumors grown in s-SEMA3A mice
displayed increased extravasated dextran (Figure 5B).
Moreover, these tumors displayed increased tissue hypox-
ia, as revealed by pimonidazole staining (Figure 5C).
These data suggest that systemic expression of SEMA3A,
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ited by SEMA3A; ***P0.002. Results are representative of at least
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-SMA (lower row) to assess vessel structure. Morphometric
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though promoting a prometastatic tumor microenviron-
ment (enhanced hypoxia and vascular leakiness), effi-
ciently inhibits metastatic dissemination of tumor cells by
exerting direct effects on tumor cells.
Tumor-Targeted Delivery of SEMA3A by
TIE2-Expressing Monocytes Inhibits
Tumor Progression
A subset of circulating and tumor-infiltrating proangiogenic
monocytes/macrophages, which are characterized by the
expression of the angiopoietin receptor Tie2 (Tie2-expressing
monocytes [TEMs]), were recently exploited to deliver
interferon- to the tumor site.35 These cells are derived from
the bone marrow and can be used as cellular vehicles to
achieve targeted delivery of inhibitory molecules to tumors,
without generating high systemic blood concentrations of the
secreted factor.36 To accomplish TEM-mediated delivery of
SEMA3A to tumors, we produced LVs expressing the murine
SEMA3A cDNA under the control of promoter/enhancer
sequences of the Tie2 gene (Tie2-3A LV). Consistent with the
notion that Tie2 is highly expressed in endothelial cells, the
Tie2-3A LV expressed SEMA3A efficiently in brain endo-
thelial cells but not in embryonic kidney HEK-293T cells in
vitro (see Supplemental Figure VIIA).
Hematopoietic stem/progenitor cells obtained from the BM
of FVB-Tie2-GFP transgenic mice37 or FVB-WT mice were
then transduced with the Tie2-3A LV and transplanted into
lethally irradiated mice, to obtain mice with TEM-specific
expression of m-SEMA3A (Tie2-SEMA3A mice; see sche-
matic procedure in Supplemental Figure VIIB). Moreover,
mice transplanted with BM cells transduced with Tie2-EV
LVs were used as controls. Tie2-SEMA3A mice were recon-
stituted long-term by SEMA3A gene-modified BM cells and
did not show any obvious signs of toxicity (data not shown).
Six weeks after hematopoietic stem/progenitor cell trans-
plantation, 66cl4 mammary carcinoma cells were injected
subcutaneously in both Tie2-3A and control mice to study
tumor development. At the end of the experiments (6 weeks
after tumor cell injection), we found that both primary tumor
weight (Figure 6A) and metastatic spreading (Figure 6B)
were reduced in Tie2-3A mice as compared with the controls.
Notably, Tie2-Sema3A expression did not affect the number
of circulating TEMs as estimated by fluorescence-activated
cell sorting analysis of Tie2CD115 cells in the peripheral
blood of Tie2-3A and Tie2-EV mice (1.020.39% versus
1.260.45% of total leukocytes, respectively; P0.69; n6).
Moreover we found blood vessel–associated Tie2 cells17,29
positive for SEMA3A expression (Figure 6C).
Immunostaining of tumor sections revealed that TEM-
mediated SEMA3A delivery phenocopied the vascular
changes observed on systemic delivery of SEMA3A. In
particular, CD31 immunostaining indicated that tumors
grown in Tie2-Sema3A mice had reduced relative blood
vessel area (Figure 6D). Moreover, SEMA3A greatly im-
paired vessel functionality, as revealed by labeling perfused
blood vessels with high-molecular-weight (2 MDa) TRITC-
conjugated dextran injected in the circulation of tumor-
bearing mice (Figure 6E). Consistent with the data observed
in mice that received systemic SEMA3A, pericyte coverage
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Figure 6. TEM cell–mediated SEMA3A delivery to the tumor site
inhibits tumor progression. A and B, 66cl4 tumor growth in nude
mice transplanted with Tie2-3A–transduced bone marrow). TEM
cell–mediated delivery of SEMA3A reduced tumor growth (A)
and metastatic dissemination (B) (n20; **P0.01, *P0.05; the
graphs display average valuesSEMs). C, Sections from
Tie2-EV and Tie2-3A 66cl4 tumors were coimmunostained to
detect Tie2 (red) and myc-tagged SEMA3A (green). Scale bars,
20 m. D, Sections from the same tumors as described above
were immunostained for CD31 (red) revealed that TEM cell–
mediated delivery decreased vessel area compared with con-
trols (n12, **P0.01; the graphs display average
valuesSEMs). Scale bars, 50 m. E, Functional and blood-
perfused vessels were labeled by injecting nonpermeable high-
molecular weight (2-MDa) tetramethylrhodamine-dextran (red) in
tumor-bearing mice (same as described above), as well as
staining for CD31 (in blue). TEM cell–mediated delivery of
SEMA3A reduced the number of perfused vessels (identified by
double staining for CD31 in blue and fluorescent dextran in red
(n6 *P0.05). Scale bars, 20 m. F, Tumor sections from con-
trol and Tie2-3A 66cl4 tumors were coimmunostained for CD31
(red) and the pericyte marker -SMA (green). Morphometric
analysis (second row) showed less pericyte-covered tumor ves-
sels in Tie2-3A tumors compared with controls (n12,
**P0.01; the graphs display average valuesSEMs). Scale bar,
20 m. G, Sections as described above were immunostained
for CD31 (red), cleaved-caspase 3 (green), and Topro3 (blue).
SEMA3A treated tumors displayed an increase in apoptotic ves-
sels (n12, **P0.01; the graphs display average
valuesSEMs). White arrows point to apoptotic vessels. Scale
bars, 20 m. H, Tumors were also immunostained for the
hypoxic marker pimonidazole (PIMO; red) and for the nucleic
marker Topro3 (blue). Morphometric analysis showed an
increase in hypoxia in Tie2-3A tumors compared with controls
(n6; *P0.05). Scale bars, 100 m.
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of tumor vessels in Tie2-Sema3A mice was reduced (Figure
6F). Moreover, double staining for cleaved caspase-3 and
CD31 showed that Tie2-Sema3A tumors contained a signif-
icantly increased fraction of apoptotic endothelial cells com-
pared with controls (Figure 6G). The reduced blood vessel
functionality in tumors grown in Tie2-Sema3A mice trans-
lated in an increased tumor hypoxia, as assessed by pimonida-
zole staining (Figure 6H). These data indicate that TEM-
mediated delivery of SEMA3A can impair blood vessel
formation and functionality, as well as the growth of primary
tumors and their metastatic dissemination to the lungs.
Discussion
Solid tumors cannot grow or spread without the formation of
new blood vessels; this finding has driven several studies in
the last decades aimed to find antiangiogenic therapeutic
strategies. In this work, we have investigated the role of
SEMA3A in tumor angiogenesis, tumor growth and meta-
static dissemination using 3 different delivery strategies: (1)
tumor cell-based gene transfer, (2) systemic expression of
SEMA3A in mice, and (3) tumor macrophage-mediated local
delivery in tumors. Although it has been reported that an
autocrine loop of SEMA3A may inhibit the growth of tumor
cells expressing high levels of NP1,7 we did not observe this
effect in various tumor cell models analyzed in this study.
However, SEMA3A did inhibit tumor cell migration in an
NP1-dependent manner.
Recent studies have emphasized that tumor growth and
metastatic dissemination is regulated not only by blood vessel
density but, most importantly, by blood vessel functional-
ity.34,38 The tumor vasculature typically displays a high-
density irregular network, and it is often characterized by
inadequate coverage by mural cells; this inadequate coverage
has also been implicated in the metastatic spreading.39 An
abnormal tumor vasculature is generally poorly perfused,
which results in enhanced tumor cell apoptosis, necrosis and
hypoxia. Therapeutic approaches aimed at further reducing
vessel perfusion usually impair tumor growth; this may also
affect metastasis formation as a secondary effect to the
reduction of primary tumor burden. However, it has recently
been shown that tumor shrinkage achieved by antiangiogenic
drugs interfering with vascular endothelial growth factor
signaling may instead be associated with increased metastatic
spreading.13,14 Although the molecular mechanisms responsi-
ble for these processes are currently unknown, it has been
proposed that hypoxic tissues switch on a transcriptional
“escape” program, leading to increased cancer cell
invasiveness.40
In our study, we demonstrated that systemic or local
expression of SEMA3A impairs tumor angiogenesis and
reduces the number of pericyte-coated vessels. This resulted
in decreased vessel perfusion and increased hypoxia, in
association with tissue apoptosis and necrosis; thus,
SEMA3A-treated tumors were significantly smaller than
controls. Importantly, although hypoxic and apoptotic, these
tumors did not become invasive and metastatic, suggesting
that SEMA3A could concomitantly interfere with cancer cell
behavior. In fact, we showed that, independently from its
paracrine activity on tumor vasculature, SEMA3A inhibits
the metastatic dissemination by acting directly on cancer cell
migration in NP1-dependent manner. This was demonstrated
by distinct experimental strategies: (1) NP1-neutralizing an-
tibodies abrogated SEMA3A-dependent inhibition of tumor
cell migration, and (2) NP1 expression knockdown in cancer
cells prevented SEMA3A-mediated inhibition of metastatic
dissemination in vivo.
Importantly, the potency of the antiangiogenic activity of
SEMA3A will depend on the active concentration that is
reached within the tumor site and tumor vessels and on its
ability to counterbalance the effect of proangiogenic factors
usually present in the tumor microenvironment. For instance,
the local delivery of SEMA3A in a transgenic oncogene-
driven model of pancreatic islet cell carcinogenesis resulted
in a mild and transient antiangiogenic effect, which eventu-
ally subsided into vessel “normalization” rather than further
disruption.12 This resulted in a moderate SEMA3A-
dependent inhibition of tumor growth that was sufficient to
prolong overall survival by delaying the occurrence of lethal
hyperinsulinemia; however, time persistence of tumor sup-
pression and potential metastatic progression were not inves-
tigated. In our present study, by exploiting multiple experi-
mental tumor models and delivery routes based on LV-
mediated gene transfer, we demonstrated that SEMA3A is a
strong antiangiogenic factor novel in its kind, because it can
impair tumor growth and prevent metastatic dissemination. In
our experiments, the majority of vessels in SEMA3A-
treated tumors were severely disrupted compared with
controls, indicating a persistent inhibitory activity by the
semaphorin, which overpowered local proangiogenic fac-
tors and resulted in sustained tumor suppression during the
entire experiment. Moreover, we showed that the meta-
static spreading was not increased in presence of
SEMA3A, because this versatile antiangiogenic factor also
directly inhibited cancer cell migration.
In conclusion, our work provides proof of concept, in
multiple preclinical models, that the antiangiogenic activity
of SEMA3A may be exploited to effectively inhibit tumor
growth and metastatic progression.
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SUPPLEMENTAL MATERIAL 
 
Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis 
and Progression in Mouse Tumor Models  
by Andrea Casazza et al. 
 
 
 
SUPPLEMENTAL METHODS 
 
Real-time Quantitiative PCR analysis of NP1 gene expression. Total RNA 
from tumor cell lines was isolated by using RNeasy Protect Mini Kit (Qiagen) 
according to manufacturer’s instructions. cDNA preparation was performed 
according to standard procedures, using M-MLV Reverse Transcriptase 
(Promega) and oligo-dT primers (Sigma-Genosys). Q-PCR analysis was 
performed using the Applied Biosystems 7900HT Fast Real-time PCR System 
and Taqman probes Hs00826128_m1 (human NP1) and Mm00435372_m1 
(mouse NP1). Gene expression was quantified as relative number of transcripts 
compared to HPRT (Taqman probes: Hs99999909_m1, Mm01545399_m1, 
human and murine, respectively).  
 
ELISA-based SEMA3A quantification of SEMA3A in mouse sera. Anti-
SEMA3A antibody (Abcam) was adsorbed to 96-well ELISA plates overnight at 
4°C. After blocking non-specific binding, multiple dilutions of serum samples and 
a standard curve of purified SEMA3A (0–100 ng/mL) were incubated overnight 
at 4°C. Captured SEMA3A was revealed with anti-myc-tag antibodies 
conjugated with horseradish peroxidase (Roche). Enzymatic reaction was 
developed in the presence of tetramethylbenzidine (Sigma) as substrate, and 
the colorimetric analysis was performed with ELx-800 reader (BioTek 
Instrument, Inc.). SEMA3A concentration in serum samples was determined by 
interpolation of absorbance values with those of the standard curve. 
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 HUVEC-Tumor Cell Co-Culture Assay. HUVEC cells repulsion by co-cultured 
tumor cells was measured as described previously (Bielenberg et al., 2004), 
with the following modifications. HUVEC cells were grown to confluence into 24-
well cell culture dishes (Corning Inc.) onto gelatin-coated glass cover slips. The 
endothelial cell monolayer was washed twice and 4 x 103 MDA-MB435 tumor 
cells were seeded out on the monolayer, transduced with SEMA3A, were 
seeded onto it in D-MEM complete medium. Co-cultures were incubated for 24h 
and 48 h, before analysis. Cells were then fixed with PAF and subjected to 
immunostaining. Endothelial cells were identified by immunocytochemical 
staining with anti-CD31 antibodies (DAKO). Apoptotic cells were identified with 
anti-cleaved Caspase-3 (Cell Signaling). 
 
Cited References 
Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun 
M. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly 
vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest. 
2004;114:1260-1271. 
 
 
 
 
SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure I.  
Tumor growth is inhibited by cell-based therapy with SEMA3A. 
A: Western blotting analysis revealed the expression of myc-tagged h-SEMA3A 
in protein lysates of LV-transduced human MDA-MB-435 (MDA). Control cells 
were transduced with an empty vector (EV). 
B: Cell growth curves show that MDA-EV and MDA-3A+ tumor cells grew at 
comparable rates in low serum conditions (1% FBS), 
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C: MDA-EV and 3A+ cell migration was analyzed in a Transwell migration assay. 
MDA-EV and 3A+ cells were allowed to migrate towards 1% FBS-containing 
medium, supplemented with a control antibody or a NP1-blocking antibody. The 
migration of 3A+ cells was reduced compared to control cells, but NP1-
neutralizing antibodies prevented the inhibitory effect of SEMA3A. Asterisks (*) 
indicate statistically significant differences compared to MDA EV cells treated 
with control Ab ***p<0.001 while hatch (##) indicate significance compared to 
MDA-3A+ treated with control Ab ## p<0.01. 
D-E: SEMA3A-expressing and EV-control transduced tumor cells described 
above were transplanted subcutaneously into athymic mice. SEMA3A 
expression significantly reduced tumor growth (D) and metastatic dissemination 
to the lungs (E) (n=6; ***p<0.001, **p<0.01, *p<0.05; with 2-Way ANOVA and 
Students t-test). 
F-G: MDA-EV and 3A+ tumor sections were to immunostaining for activated-
caspase3 to detect apoptotic cells (in green); CD31 marker was stained to 
identify endothelial cells (red); DAPI stained all nuclei (blue). SEMA3A 
increased tumor cell apoptosis (i.e. caspase+ cells/total cell number; panel F) 
and decreased vessel area (panel G) (n=6; *p<0.05, **p<0.01). Scale bars: 20 
µm (panel F) and 50 µm (panel G). 
H: Immunostaining of MDA-EV and 3A+ tumor sections revealed the expression 
of secreted myc-tagged SEMA3A (green); nuclei were stained with DAPI (blue). 
Scale bars: 20 μm. 
 
 
Supplemental Figure II.  
Neuropilin-1 expression in tumor models. 
A: Neuropilin-1 (NP1) expression in three cancer cell lines used in our study 
was determined by Q-PCR. The graph displays the relative number of NP1 
mRNA transcripts compared to those of HPRT house-keeper gene in each of 
the models.  
 by guest on June 12, 2012http://atvb.ahajournals.org/Downloaded from 
B: Neuropilin-1 (NP1) and Plexin-A1 expression in 4T1, 66cl4 and MDA control 
EV-cells and SEMA3A-transduced cells was determined by Q-PCR.  
C: 66cl4 and 4T1 tumor tissue sections were stained to reveal NP1 (green) and 
CD31-positive endothelial cells (red)(n=5). 
 
 
Supplemental Figure III.  
SEMA3A increase necrosis and hemhorragis in 4T1 and 66cl4 Tumors. 
Tissue sections of control-EV and SEMA3A+ tumors (66cl4 and 4T1, as 
indicated) were stained with heamatoxylin and eosin to detect necrotic (N) and 
hemorrhagic (H) areas (n= 6; *p <0.05; **p <0.01). Scale bars: 100 μm.  
 
 
Supplemental Figure IV.   
SEMA3A induce endothelial cell apoptosis in vitro. 
MDA-3A+ and MDA-EV were co-cultured with HUVEC cells during 24 and 48 
hours. SEMA3A induced endothelial apoptosis as measured by staining for the 
endothelial marker CD31 and the apoptosis marker cleaved caspase-3 (bottom 
panel, number of field counted=10; ***p<0,001). Green arrows indicate 
apoptotic cells while white arrow indicates tumor cells. 
 
 
Supplemental Figure V.   
SEMA3A inhibits lymphangiogesis. 
Tissue sections of 4T1-EV and 3A+ tumors were co-stained to reveal the network of 
lymphatic vessels, by using the marker LYVE-1, in association with CD31 and F4/80. 
SEMA3A expression reduced LYVE-1+F4/80-CD31- lymphatic vessels by 50% 
compared to controls in both tumor models (n=6; **p<0.01, *p<0.05). Scale bars: 20 µm.  
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Supplemental Figure VI.   
Systemic delivery of SEMA3A in mice.  
Liver sections from control and s-Sema3A mice were stained with anti-myc to detect 
myc-tagged Sema3A expression. Scale bars: 100 μm. 
 
 
Supplemental Figure VII.  
Generation of Mice with TEM-Specific Expression of SEMA3A.  
A: Tie2-2 driven expression of SEMA3A is detected by western blotting analysis 
in brain endothelial cells (bEND) but not in HEK-293T cells.  
B: Schematic figure describing the experimental procedure applied to generate 
chimeric mice with TEM-Specific Expression of SEMA3A.  
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